Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — Q4 2021 Earnings Presentation
43 slides from Lytix Biopharma ASA's earnings presentation, Feb 17, 2022
Slide 1: Lytix Biopharma AS: Fourth quarter 2021 presentation
Lytix Biopharma AS At the forefront of innovative cancer therapy Fourth quarter 2021 presentation February 17, 2022
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Today's presenters
Today's presenters Øystein Rekdal / CEO and co-founder • Dr. Rekdal’s post-doctoral research forms the basis of Lytix Biopharma’s oncolytic molecule platform. • Over the last years Rekdal has been instrumental in the development of intra-tumoral therapy of LTX-315 from preclinical to clinical ‘proof
Slide 4: Lytix Biopharma in brief
Lytix Biopharma in brief Lytix is a biotech company headquartered in Oslo, Norway. The company was listed at Euronext Growth in June 2021. Lytix has developed a unique and proprietary technology platform for in situ vaccination. Lytix aims to accelerate progression of this unique platform, building
Slide 5: Highlights of the quarter
Highlights of the quarter
Slide 6: Highlights of the fourth quarter 2021
Highlights of the fourth quarter 2021 Lytix’ partner Verrica Pharmaceutical’s approval for Phase II study in the US for skin cancer diseases ‒ Verrica received US FDA approval to initiate its Phase II study with LTX-315 for the treatment of basal cell carcinoma ‒ First patient due to be dosed in the
Slide 7: Highlights of the fourth quarter 2021
Highlights of the fourth quarter 2021 Treatment completed in Phase II study for patients with soft tissue sarcoma, ‒ Data to be presented at international conference Q2/Q3 Key pre-clinical data presented at SITC (Society for Immunotherapy of Cancer) annual meeting One additional patent granted in th
Slide 8: Oncolytic molecules solve one of the major challenges in current cancer therapy
Oncolytic molecules solve one of the major challenges in current cancer therapy Tumors consist of many Source: GlobalData High-Prescriber Survey (December, 2020) different cancer cells with different mutations
Slide 9: Oncolytic molecules provide a new in situ vaccination principle
Oncolytic molecules provide a new in situ vaccination principle TREATED TUMOR A cancer cell before treatment Exposure of mutations (tumor antigens) from all dead cancer cells LYMPH NODE Generating T cells that recognize the A cancer cell after treatment different mutations (tumor antigens) BLOOD VES
Slide 10: A unique technology platform with high commercial potential
A unique technology platform with high commercial potential Product Combination Population Preclinical Phase I Phase II Phase III Collaborations candidate partner ATLAS-IT-05 Patients progressed Pembrolizumab on checkpoint (Keytruda®) inhibitors N/A LTX-315 Basal cell carcinoma (monotherapy) ATLAS-I
Slide 11: Lytix targets large market opportunities
Lytix targets large market opportunities HEAD AND MALIGNANT NECK CANCER MELANOMA 130.000* 200.000* new patients diagnosed new patients diagnosed 3.7 Bn USD* 5.5 Bn USD* estimated indication value estimated indication value LIVER BREAST CANCER CANCER 260.000* 970.000* new patients diagnosed new patie
Slide 12: Clinical/operational update
Clinical/operational update
Slide 13: Verrica's approval for Phase II study in the US for skin cancer
Lytix partner Verrica Pharmaceutical’s approval for Phase II study in the US for skin cancer diseases Verrica in-licensed LTX-315 for certain skin cancer types in August 2020 Verrica intends to focus on the most common malignancy in humans1, as the lead indications ‒ Estimated 5.4 million diagnoses
Slide 14: Verrica deal terms: milestones and royalties
Lytix partner Verrica Pharmaceutical’s approval for Phase II study in the US for skin cancer diseases, Regulatory milestones based on development goals and sales milestones at >100 mill. USD Royalty rates from the low double-digits to the mid-teens based on net sales USD Together, basal cell and cut
Slide 15: Kick-off for Phase II study with LTX-315 (ATLAS-IT-05)
Kick-off for Phase II study in the US with our lead cancer drug candidate LTX-315 (ATLAS-IT-05) Building value in metastatic setting through clinical Phase II study in the US A Phase II combination study evaluating LTX-315 and pembrolizumab in patients with solid tumors First patient dosed at MD And
Slide 16: Fully enrolled Phase II study in soft tissue sarcoma (ATLAS-IT-04)
Fully enrolled Phase II study for patients with soft tissue sarcoma (ATLAS-IT-04) A proof of principle study ‒ evaluating LTX-315 in combination with adoptive T-cell therapy in advanced soft tissue sarcoma patients Treatment completed Data analysis ongoing ‒ Clinical efficacy ‒ LTX-315`s ability to
Slide 17: LTX-401, a next generation oncolytic molecule
LTX-401 – a next generation oncolytic molecule expanding the application of in situ vaccination A pre-clinical safety program evaluating LTX-401 is ongoing at Aptuit in Italy and is expected to complete 2022 A second-generation oncolytic molecule with chemical properties suited for deep seated lesio
Slide 18: LTX-401 targeting liver cancer
LTX-401, a next generation oncolytic molecule targeting liver cancer LTX-401: Promising results in liver cancer Number of deaths in 2020, all ages animal models Third most common cause of cancer related death globally, where hepatocellular carcinoma accounts for 80-90 % of the cases LTX-401 treatmen
Slide 19: Summary and priorities for 2022
Summary and priorities for 2022 Highlights of second half 2021 Priorities for 2022 Kick-off for Phase II study in the Our Phase II combination trial, US with our lead cancer drug ATLAS-IT-05, is on track to complete candidate LTX-315 enrollment by the end of 2022 Fully enrolled Phase II study for A
Slide 20: Financials
Financials
Slide 21: Key figures – profit and loss
Key figures – profit and loss Unaudited Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q4 2021 Q4 2020 H2 2021 H2 2020 FY 2021 FY 2020 Total operating income 719 1,951 2,626 5,433 25,827 6,678 Total operating expenses (17,087) (14,598) (37,790) (33,372) (73,844) (49,050) Loss from
Slide 22: Key figures – balance sheet
Key figures – balance sheet Unaudited Amounts in NOK thousands 31.12.2021 31.12.2020 Assets Trade and other receivables 5,680 4,168 Cash and cash equivalents 197,282 28,450 Total assets 202,962 32,617 Shareholder's equity and liabilities Total equity 189,624 19,889 Total liabilities 13,338 12,728 To
Slide 23: Company presentation
Company presentation
Slide 24: First in class entering Phase II studies in U.S.
FIRST IN CLASS ENTERING PHASE II VALIDATED STUDIES IN U.S. Nobel Price winner at Unique therapeutic LTX-315 in Phase II the advisory board approach development in US led by with universal # 1 cancer hospital Commercial deal within mechanism of action globally skin cancer Promising efficacy signals V
Slide 25: First in class entering Phase II studies in U.S.
FIRST IN CLASS ENTERING PHASE II VALIDATED STUDIES IN U.S.
Slide 26: Oncolytic molecules solve one of the major challenges in current cancer therapy
Oncolytic molecules solve one of the major challenges in current cancer therapy Tumors consist of many Source: GlobalData High-Prescriber Survey (December, 2020) different cancer cells with different mutations
Slide 27: Oncolytic molecules provides a new in situ vaccination principle
Oncolytic molecules provides a new in situ vaccination principle TREATED TUMOR A cancer cell before treatment Exposure of mutations (tumor antigens) from all dead cancer cells LYMPH NODE Generating T cells that recognize the A cancer cell after treatment different mutations (tumor antigens) BLOOD VE
Slide 28: LTX-315 is effective in hard to treat cancer models
LTX-315 is effective in “hard to treat” cancer models B16F10 MELANOMA BRAF MUTATED MELANOMA No effect of chemotherapy or immune checkpoint inhibitors in the BRAF mutated melanoma model Liao, Cell Stress, 2019
Slide 29: Case study: Anti cancer effects in distant non-treated tumors
Case study: Proof of Principle - Anti cancer effects in distant non- treated tumors confirmed in cancer patients One tumor treated in the lower back Spicer, Clin. Cancer Res., 2021
Slide 30: Immune checkpoint inhibitors solve a different problem in cancer therapy
Immune checkpoint inhibitors solve a different problem in cancer therapy Immune checkpoint inhibitors cure some patients Responders Failures MALIGNANT MELANOMA 60-89% TRIPLE NEGATIVE BREAST CANCER 82-95% Some cancers can protect themselves HEAD & NECK 82-87% by activating brakes in the immune system
Slide 31: Immune checkpoint inhibitors solve a different problem in cancer therapy
Immune checkpoint inhibitors solve a different problem in cancer therapy Immune checkpoint inhibitors cure some patients Responders Failures MALIGNANT MELANOMA 60-89% TRIPLE NEGATIVE BREAST CANCER 82-95% Immune checkpoint Some cancers can inhibitors protect themselves HEAD & NECK 82-87% can remove t
Slide 32: Combination therapy with immune checkpoint inhibitors
Combination therapy with immune checkpoint inhibitors Oncolytic molecules generate T cells that recognize different cancer cells + Immune checkpoint inhibitors keeps the brakes off and make the T cells work more efficiently
Slide 33: Case study: LTX-315 + checkpoint inhibitor in breast cancer patient
Case study: Proof of Principle - LTX-315 + checkpoint inhibitor showed effects not obtained with same checkpoint inhibitor alone in breast cancer patient The checkpoint inhibitor pembrolizumab alone • No effect in liver metastasis • Chemotherapy 2. 5 % overall response rate (ORR) LTX-315 + pembroliz
Slide 34: First in class entering Phase II studies in U.S.
FIRST IN CLASS ENTERING PHASE II VALIDATED STUDIES IN U.S.
Slide 35: Clinical study with LTX-315 and pembrolizumab ongoing in US
Clinical study with LTX-315 and the immune checkpoint inhibitor pembrolizumab is ongoing in US The study is led by MD Anderson Hospital ‒ Ranks as No. 1 globally in cancer care
Slide 36: First in class entering Phase II studies in U.S.
FIRST IN CLASS ENTERING PHASE II VALIDATED STUDIES IN U.S.
Slide 37: Science behind Lytix' technology documented by leading research institutions
Science behind Lytix’ technology documented by world leading cancer research institutions Multiple collaborations leading to 50+ peer reviewed scientific publications, demonstrating the potential of oncolytic molecules
Slide 38: Nobel laureate Jim Allison is a member of our scientific advisory board
Nobel laureate Jim Allison, who discovered the first immune checkpoint inhibitor, is a member of our scientific advisory board “The ability of an activated immune response to generate a diverse T-cell repertoire that adapts to heterogeneous and genetically unstable tumors (…) make it absolutely esse
Slide 39: Lytix investor PBM Capital
Lytix investor - the US healthcare specialist PBM Capital invest in game changing technologies
Slide 40: Our technology already commercially validated
Our technology already commercially validated US-based biotech Regulatory milestones focused on novel based on development treatments for skin goals and sales milestones diseases at >100 mill. USD License of LTX-315 Royalty rates from the low for the treatment double-digits to the mid- of certain sk
Slide 41: Summary
Summary
Slide 42: Why we will succeed
Why we will succeed UNIQUE APPROACH SCIENCE VALIDATION EXECUTION Lytix’s molecules Science confirmed by Commercial deal within Management represent the missing top notch US and skin cancer Board piece European cancer Advisory Board research institutions US health specialist Competent investors Ideal
Slide 43: Q&A
Q&A IR enquiries: ole.peter.nordby@lytixbiopharma.com